PACAP intraperitoneal treatment suppresses appetite and food intake via PAC1 receptor in mice by inhibiting ghrelin and increasing GLP-1 and leptin

Pituitary adenylate cyclase-activating peptide (PACAP) is expressed within the gastroenteric system, where it has profound physiological effects. PACAP was shown to regulate food intake and thermogenesis centrally; however, PACAP peripheral regulation of appetite and feeding behavior is unknown. Therefore, we studied PACAP's effect on appetite and food intake control by analyzing feeding behavior and metabolic hormones in PAC1-deficient (PAC1–/–) and age-matched wild-type (WT) mice intraperitoneally injected with PACAP_1–38 or PACAP_1–27 before the dark phase of feeding. Food intake and feeding behavior were analyzed using the BioDAQ system. Active ghrelin, glucagon-like peptide-1 (GLP-1), leptin, peptide YY, pancreatic polypeptide, and insulin were measured following PACAP_1–38 administration in fasted WT mice. PACAP_1–38/PACAP_1–27 injected into WT mice significantly decreased in a dose-dependent manner cumulative food intake and reduced bout and meal feeding parameters. Conversely, PACAP_1–38 injected into PAC1–/– mice failed to significantly change food intake. Importantly, PACAP_1–38 reduced plasma levels of active ghrelin compared with vehicle in WT mice. In PAC1–/– mice, fasting levels of active ghrelin, GLP-1, insulin, and leptin and postprandial levels of active ghrelin and insulin were significantly altered compared with levels in WT mice. Therefore, PAC1 is a novel regulator of appetite/satiety. PACAP_1–38/PACAP_1–27 significantly reduced appetite and food intake through PAC1. In PAC1–/– mice, the regulation of anorexigenic/orexigenic hormones was abolished, whereas active ghrelin remained elevated even postprandially. PACAP significantly reduced active ghrelin in fasting conditions. These results establish a role for PACAP via PAC1 in the peripheral regulation of appetite/satiety and suggest future studies to explore a therapeutic use of PACAP or PAC1 agonists for obesity treatment.

From: Vu, J. P., Goyal, D., Luong, L., Oh, S., Sandhu, R., Norris, J., Parsons, W., Pisegna, J. R., Germano, P. M. http://ajpgi.physiology.org/cgi/content/abstract/309/10/G816?rss=1